Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 29;13(23):1976.
doi: 10.3390/cells13231976.

Advances in Induced Pluripotent Stem Cell-Derived Natural Killer Cell Therapy

Wenhua Qiao  1 , Peng Dong  2 , Hui Chen  1   2 , Jianmin Zhang  1   2
Affiliations
Review

Advances in Induced Pluripotent Stem Cell-Derived Natural Killer Cell Therapy

Wenhua Qiao et al. Cells. .

Abstract

Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system capable of killing virus-infected cells and/or cancer cells. The commonly used NK cells for therapeutic applications include primary NK cells and immortalized NK cell lines. However, primary NK cell therapy faces limitations due to its restricted proliferation capacity and challenges in stable storage. Meanwhile, the immortalized NK-92 cell line requires irradiation prior to infusion, which reduces its cytotoxic activity, providing a ready-made alternative and overcoming these bottlenecks. Recent improvements in differentiation protocols for iPSC-derived NK cells have facilitated the clinical production of iPSC-NK cells. Moreover, iPSC-NK cells can be genetically modified to enhance tumor targeting and improve the expansion and persistence of iPSC-NK cells, thereby achieving more robust antitumor efficacy. This paper focuses on the differentiation-protocols efforts of iPSC-derived NK cells and the latest progress in iPSC-NK cell therapy. Additionally, we discuss the current challenges faced by iPSC-NK cells and provide an outlook on future applications and developments.

Keywords: NK cells; cancer immunotherapy; gene editing; iPSC (induced pluripotent stem cell).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Liu S., Galat V., Galat4 Y., Lee Y.K.A., Wainwright D., Wu J. NK cell-based cancer immunotherapy: From basic biology to clinical development. J. Hematol. Oncol. 2021;14:7. doi: 10.1186/s13045-020-01014-w. - DOI - PMC - PubMed
    1. Ma F., Ho J., Du H., Xuan F., Wu X., Wang Q., Wang L., Liu Y., Ba M., Wang Y., et al. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Hematol. Oncol. 2019;37:601–608. doi: 10.1002/hon.2672. - DOI - PMC - PubMed
    1. Brudno J.N., Kochenderfer J.N. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45–55. doi: 10.1016/j.blre.2018.11.002. - DOI - PMC - PubMed
    1. Schuster S.J., Svoboda J., Chong E.A., Nasta S.D., Mato A.R., Anak Ö., Brogdon J.L., Pruteanu-Malinici I., Bhoj V., Landsburg D., et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N. Engl. J. Med. 2017;377:2545–2554. doi: 10.1056/NEJMoa1708566. - DOI - PMC - PubMed
    1. Sterner R.C., Sterner R.M. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021;11:69. doi: 10.1038/s41408-021-00459-7. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources